PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Technological Innovations Expand the Capabilities of Mass Spectrometers - The acceptance of mass spectrometric techniques in research institutions across Europe is being driven by their inherent advantages such as increased accuracy and higher throughput ratio
Technological Innovations Expand the Capabilities of Mass Spectrometers

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/09/18 - The acceptance of mass spectrometric techniques in research institutions across Europe is being driven by their inherent advantages such as increased accuracy and higher throughput ratio.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Mass spectrometry (MS) has found significant use in the pharmaceutical and biotechnology sectors, where primary applications include the characterisation of protein and other biologically active entities.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), Opportunities for the European Mass Spectrometry Markets in Basic Research Applications, finds that the market earned revenues of $562 million in 2007 and estimates this to reach $1078.8 million in 2014.

"In the field of environmental sciences, the analytical capabilities of MS platforms are extensively used in the identification of numerous toxins and pollutants," notes Frost & Sullivan Research Analyst Suraj Ramanathan. "The influence of this technology has reached areas such as forensic science. Further areas of interest include polymer analysis, environmental sciences, food safety and nutrition, drug abuse and rehabilitation, defence research and space research."

Furthermore, the discovery of disease biomarkers has helped expand the capabilities of this analysis platform. The Fourier Transform Mass Spectrometry (FTMS) segment is showing maximum growth, with a higher degree of technical innovation.

Many MS manufacturers have come out with customised research programs that suit end-user requirements. This has led to numerous research and marketing agreements between MS manufacturers and companies and research organisations over a wide spectrum.

However, one of the most important challenges facing the European mass spectrometry markets is the increase in strategic consolidations within the pharmaceutical industry, which is reducing buying power. Product pricing issues, changes in funding towards clinical research, funding from the private sector and reduced manpower for operating instruments are some of the other challenges confronting market participants.

"Compensating on logistical costs, many pharmaceutical companies have started outsourcing their R&D initiatives to countries such as India and China that are comparatively high on resources and manpower," notes Ramanathan. "This reduces the need for high-tech instruments within Europe."

With end users concerned about the shortage of skilled technicians to operate MS, manufacturers need to develop training programs to enable first-time users to familiarize themselves with the platform. Manufacturers could also regularly update end users on technological advancements in the field of study with respect to MS usage. This would aid them in applying MS in their research areas, strengthening customer relationship.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the opportunities for the European mass spectrometry markets in basic research applications, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

Opportunities for the European Mass Spectrometry Markets in Basic Research Applications is part of the Drug Discovery & Clinical Diagnostics Growth Partnership Service programme, which also includes research in the following markets: European Molecular Diagnostics Markets, European IVD Market and European Cancer Diagnostic Market, European Primary Care Diagnostics. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Opportunities for the European Mass Spectrometry Markets in Basic Research Applications
M229

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Technological Innovations Expand the Capabilities of Mass Spectrometers

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  1Click Games





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)